<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00590525</url>
  </required_header>
  <id_info>
    <org_study_id>04-13547</org_study_id>
    <secondary_id>04-13547</secondary_id>
    <nct_id>NCT00590525</nct_id>
  </id_info>
  <brief_title>Inflammation as a Predictor in Cardioversion of Atrial Fibrillation</brief_title>
  <official_title>Inflammation as a Predictor in Cardioversion of Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Creighton University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Creighton University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The laboratory test, C-Reactive Protein (CRP), has become well established as a marker of&#xD;
      inflammation. Recently a high CRP level (indicating an increase in inflammation) was&#xD;
      identified as a risk factor for atrial fibrillation. We are conducting this study with&#xD;
      patients such as yourself with atrial fibrillation who are planning to undergo cardioversion&#xD;
      to determine what sort of relationship exists between CRP levels and atrial fibrillation. We&#xD;
      will then look at success rates of converting atrial fibrillation to normal sinus rhythm,&#xD;
      compared to patients' CRP levels.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2004</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>We hypothesize that a higher hsCRP is associated with higher failure rates in patients undergoing cardioversion for atrial fibrillation</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>secondary endpoint will be if a new inflammatory disease state is diagnosed at the one-month mark.</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">45</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cardioversion</intervention_name>
    <description>Baseline hsCRP will be drawn the morning of, prior to, cardioversion. An EKG to document the patient's rhythm will be obtained at the one-month mark</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Consecutive patients undergoing DC cardioversion at The Cardiac Center electrophysiology&#xD;
        lab who meet these criteria will be enrolled.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Atrial fibrillation patients referred for DC cardioversion&#xD;
&#xD;
          -  On stable medical therapy&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Known chronic inflammatory states such as infections, rheumatoid arthritis or known&#xD;
             vasculitides.&#xD;
&#xD;
          -  Patients having undergone recent surgery or who are on steroid therapy for any reason&#xD;
             will be excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan Schima, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Creighton University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Creighton University Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2009</verification_date>
  <study_first_submitted>December 28, 2007</study_first_submitted>
  <study_first_submitted_qc>January 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2008</study_first_posted>
  <last_update_submitted>November 27, 2009</last_update_submitted>
  <last_update_submitted_qc>November 27, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 1, 2009</last_update_posted>
  <responsible_party>
    <name_title>Susan Schima, MD</name_title>
    <organization>Creighton University</organization>
  </responsible_party>
  <keyword>hsCRP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

